A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study

Advances in Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Language: Английский

---

Ascorbic Acid and Esketamine for Mental Disorders in Women with Miscarriage: A Randomized Controlled Double-Blind Trial Protocol

Neuropsychiatric Disease and Treatment, Journal Year: 2025, Volume and Issue: Volume 21, P. 815 - 825

Published: April 1, 2025

Pregnancy leads to vulnerabilities and susceptibilities mental disorders. Miscarriage, as an adverse pregnancy outcome, following curettage for treatment, add the risks of further psychiatric disorders, including depression, anxiety, insomnia, etc., current approaches prevention are unsatisfactory. Ketamine its S-enantiomer esketamine can prevent postpartum even treats depressive symptoms after miscarriage curettage, but their side effects bring limitations. Ascorbic acid (AA, Vitamin C) modulate mood enhance ketamine's antidepressant efficacy synergistically, reducing dosages potentially. The purpose this study is clarify beneficial modification AA on preventing depression other disorders in patients with painless well interaction between esketamine. This a 2×2 factorial, double-blinded, randomized, controlled trial that will recruit women undergoing curettage. A total 424 participants be recruited randomly 1:1:1:1 allocated four groups (106 each): Group A0K0 (normal saline normal saline), A0K1 esketamine), A1K0 (AA A1K1 esketamine). primary outcome incidence postoperative day 7, assessed Edinburgh Postnatal Depression Scale (EPDS). secondary outcomes include EPDS score, assessments sleep, pain, events, perianesthetic data patient satisfaction. provides clinical trial-based evidence alone or combination/interacting emerging rapid-acting Our expected suggest AA's potential application optimizing strategies promoting post-miscarriage health, possible adjunctive improvement (es)ketamine's usage antidepressants. One major limitation single-center study, results might biased due regional factors.

Language: Английский

---

Repeated administration of L-alanine to mice reduces behavioural despair and increases hippocampal mammalian target of rapamycin signalling: Analysis of gender and metabolic effects

Journal of Psychopharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

Background: The amino acid L-alanine, has been shown to be elevated in biofluids during major depression but its relevance remains unexplored. Aim: We have investigated the effects of repeated L-alanine administration on emotional behaviours and central gene expression mice. Methods: Mice received a daily, 2-week intraperitoneal injection either saline or at 100 200 mg/kg were exposed open field, light–dark box forced swim test. transporters (asc-1, ASCT2), glycine receptor subunits (GlyRs), NMDA (GluNs) mRNAs measured, together with western blots signalling protein mammalian target rapamycin (mTOR). Since modulates glucose homeostasis, peripheral metabolomes evaluated 1 H-NMR. Results: mg/kg, not both male female mice increased latency float reduced floating time test, had no effect anxious behaviour field tests. There was significant reduction encoding asc-1 ASCT2 GluN2B hippocampus following only. On blots, hippocampal immunoreactivity reduced, mTOR group. 1H-NMR revealed gender-specific changes forebrain, plasma liver only L-alanine. Conclusions: Our data suggest that may antidepressant-like involve modulation glutamate neurotransmission independently metabolism. In depression, therefore, homeostatic response pathophysiological processes, though this will require further investigation.

Language: Английский

---

The neuroplastic brain: current breakthroughs and emerging frontiers

Brain Research, Journal Year: 2025, Volume and Issue: unknown, P. 149643 - 149643

Published: April 1, 2025

Language: Английский

---

Neuropharmacology of Ketamine and Its Use in the Treatment of Major Depressive Disorder: A Review

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: April 30, 2025

Language: Английский

---

Robust Methods For Quantifying Neuronal Morphology And Molecular Signaling Reveal That Psychedelics Do Not Induce Neuroplasticity

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: March 8, 2024

Abstract Induction of neuroplasticity has become the dominant explanatory framework for rapid and sustained therapeutic effects classic psychedelics. Within this broad concept, examination morphological neuronal plasticity, such as dendritic arbor growth, is widely used to assess novel At molecular level, it been reported that serotonergic psychedelic compounds mediate dendritogenesis via master regulator TrkB, either directly BDNF/TrkB signaling potentiation or indirectly through 5-HT2A receptor. To examine these hypotheses in detail, we developed a robust multimodal screening platform unbiased, semi-automated quantification cellular morphology multiplex same cortical neurons. We found primary cultures psychedelics do not modulate TrkB receptor BDNF-TrkB signaling. also 5HT2a gene expression functional levels are low, induce contrast significant elicited by BDNF. Our results challenge recently published field indicate need rigorous experimental methods study manifestations induced clinically therapeutics.

Language: Английский

---

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: 363, P. 589 - 594

Published: Oct. 1, 2024

Language: Английский

---

Depression and the Glutamate/GABA-Glutamine Cycle

Current Neuropharmacology, Journal Year: 2024, Volume and Issue: 23(1), P. 75 - 84

Published: Aug. 16, 2024

: Many features of major depressive disorder are mirrored in rodent models psychological stress. These have been used to examine the relationship between activation hypothalamic- pituitary axis response stress, development oxidative stress and neuroinflammation, dominance cholinergic neurotransmission associated increase REM sleep pressure. Rodent also provided valuable insights into impairment glycolysis brain glucose utilization by under resulting decrease energy production reduction glutamate/GABA-glutamine cycling. The rapidly acting antidepressants, scopolamine, ketamine ECT, all raise extracellular glutamate scopolamine specifically shown cycling men rodents with corresponding short-term relief depression. nightly use gammahydroxybutyrate (GHB) may achieve more permanent results even act prophylactically prevent or recurrence GHB is a GABAB agonist restores normal balance monoaminergic inhibiting neurotransmission. It relieves GHB’s metabolism generates NADPH, key antioxidant cofactor. Its succinate, tricarboxylic acid cycle intermediate, provide cell synthesize glutamate. In both animals man, increases level

Language: Английский

---

Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression

European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 29, 2024

Changes in glutamatergic neuroplasticity has been proposed as one of the core mechanisms underlying pathophysiology depression. In consequence components synapse have explored potential targets for antidepressant treatment. The rapid effect NMDA receptor antagonist ketamine and subsequent approval its S-enantiomer (i.e. esketamine), set precedent investigation into other acting antidepressants (RAADs). this review, we discuss different We describe important clinical outcomes several key molecules targeting their applicability RAADs. Specifically, here focus on substances beyond (es)ketamine, which meaningful data from trials are available, including arketamine, esmethadone, nitrous oxide glutamate modulators. Molecules only successful preclinical settings case reports/series marginally discussed. With aim underscore critical role modulation advancing therapy, thereby possibly enhancing but also to reducing burden depression through faster therapeutic effects.

Language: Английский

---

Chronic pramipexole and rasagiline treatment enhances dendritic spine structural neuroplasticity in striatal and prefrontal cortex neurons of rats with bilateral intrastriatal 6-hydroxydopamine lesions

Journal of Chemical Neuroanatomy, Journal Year: 2024, Volume and Issue: 141, P. 102468 - 102468

Published: Oct. 9, 2024

Parkinson's disease manifests as neurological alterations within dendritic spines in the striatal and neocortical brain regions, where their functionality closely correlates with morphology. However, impact of current pharmacotherapy on spine neuroplasticity, crucial for novel drug development psychiatric disorders, remains unclear. This study investigated effects 6-OHDA intrastriatal bilateral lesions male adult rats behavior neuroplasticity cortical neurons. Furthermore, it evaluated influence chronic co-administration pramipexole (PPX), a D3 receptor agonist, rasagiline (Ras), selective MAO-B inhibitor, these alterations. Lesioned animals exhibited impaired balance behavior, no improvement following PPX-Ras treatment. The lesion decreased density caudate putamen (CPU) spiny projection neurons (SPNs), change unaffected by treatment, though increased mushroom reduced stubby In nucleus accumbens (NAcc) SPNs prefrontal cortex layer 3 (PFC-3) pyramidal cells, remained unaltered, but bifurcated NAcc, while increasing decreasing PFC-3 lesioned rats. These findings emphasize importance promising targets innovative pharmacotherapies disease.

Language: Английский

---